Predictors of placebo group decline in the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 14, Issue 3, 2008, Pages 301-311

  Irizarry, Michael C ^a,b,c   Webb, David J ^b,c   Bains, Chanchal ^b,c   Barrett, Steven J ^b,c   Lai, Robert Y ^b,c   Laroche, Janette P ^b,c   Hosford, David ^b,c,d   Maher Edwards, Gareth ^b,c   Weil, John G ^b,c  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Targacept ^*

^d Targacept   (United States)

Author keywords

ADAS cog; Alzheimer's disease; Clinical trials; MMSE; Rosiglitazone

Indexed keywords

AGED; ALZHEIMER DISEASE; ALZHEIMER'S DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ACTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM;

EID: 47849132215     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-14304     Document Type: Article

References (34)

1. Diagnostic and Statistical Manual of Mental Disorders DSMIV, 4th ed. American Psychiatric Association, 1994.
2. P.S. Aisen, K.L. Davis, J.D. Berg, K. Schafer, K. Campbell, R.G. Thomas, M.F. Weiner, M.R. Farlow, M. Sano, M. Grundman and L.J. Thal, A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study, Neurology 54 (2000), 588-593.
3. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas and L.J. Thal, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA 289 (2003), 2819-2826.
4. K.M. Bellew, J.G. Pigeon, P.E. Stang, W. Fleischman, R.M. Gardner and W.W. Baker, Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type, Alzheimer Dis Assoc Disord 18 (2004), 208-213.
5. J. L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D.A. Carusi and J. Gornbein, The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia, Neurology 44 (1994), 2308-2314.
6. P.M. Doraiswamy, F. Bieber, L. Kaiser, K.R. Krishnan, J. Reuning-Scherer and B. Gulanski, The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials, Neurology 48 (1997), 1511-1517.
7. P.M. Doraiswamy, L. Kaiser, F. Bieber and R.L. Garman, The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease, Alzheimer Dis Assoc Disord 15 (2001), 174-183.
8. R.H. Dworkin, J. Katz and M.J. Gitlin, Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain, Neurology 65 (2005), S7-S19.
9. M.F. Folstein, S.E. Folstein and P.R. McHugh, Mini-mental state. A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 12 (1975), 189-198.
10. K.S. Fowler, M.M. Saling, E.L. Conway, J.M. Semple and W.J. Louis, Computerized neuropsychological tests in the early detection of dementia: prospective findings, J Int Neuropsychol Soc 3 (1997), 139-146.
11. D. Galasko, I. Abramson, J. Corey-Bloom and L.J. Thal, Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease, Neurology 43 (1993), 1559-1563.
12. D. Galasko, J. Corey-Bloom, L.J. Thal, Monitoring progression in Alzheimer's disease, J Am Geriatr Soc 39 (1991), 932-941.
13. S. Gauthier, B. Vellas, M. Farlow and D. Burn, Aggressive course of disease in dementia, Alzheimers Dementia 2 (2006), 210-217.
14. M. Gold, Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease, J Clin Psychiatry 68 (2007), 430-438.
15. V.C. Hachinski, L.D. Iliff, E. Zilhka, G.H. Du Boulay, V.L. McAllister, J. Marshall, R.W. Russell and L. Symon, Cerebral blood flow in dementia, Arch Neurol 32 (1975), 632-637.
16. J. Harrison, S.L. Minassian, L. Jenkins, R.S. Black, M. Koller and M. Grundman, A neuropsychological test battery for use in Alzheimer disease clinical trials, Arch Neurol 64 (2007), 1323-1329.
17. A. Kurz, M. Farlow, P. Quarg and R. Spiegel, Disease stage in Alzheimer disease and treatment effects of rivastigmine, Alzheimer Dis Assoc Disord 18 (2004), 123-128.
18. R. Lindeboom, B. Schmand, R. Holman, R.J. de Haan and M. Vermeulen, Improved brief assessment of cognition in aging and dementia, Neurology 63 (2004), 543-546.
19. C.A. Martins, A. Oulhaj, C.A. de Jager and J.H. Williams, APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model, Neurology 65 (2005), 1888-1893.
20. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 (1984), 939-944.
21. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, M. Grundman, M. Sano, L. Bieliauskas, D. Geldmacher, C. Clark and L.J. Thal, Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study, Alzheimer Dis Assoc Disord 11(Suppl 2) (1997), S13-S21.
22. J.M. Orgogozo, G.W. Small, G. Hammond, B. Van Baelen and S. Schwalen, Effects of galantamine in patients with mild Alzheimer's disease, Curr Med Res Opin 20 (2004), 1815-1820.
23. C. Randolph, M.C. Tierney, E. Mohr and T.N. Chase, The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity, J Clin Exp Neuropsychol 20 (1998), 310-319.
24. M.A. Raskind, E.R. Peskind, T. Wessel and W. Yuan, Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension, Neurology 54 (2000), 2261-2268.
25. M.E. Risner, A.M. Saunders, J.F. Altman, G.C. Ormandy, S. Craft, I.M. Foley, M.E. Zvartau-Hind, D.A. Hosford and A.D. Roses, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease, Pharmacogenomics J 6 (2006), 246-254.
26. S.L. Rogers, M.R. Farlow, R.S. Doody, R. Mohs and L.T. Friedhoff, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group, Neurology 50 (1998), 136-145.
27. W.G. Rosen, R.C. Mohs and K.L. Davis, A new rating scale for Alzheimer's disease, Am J Psychiatry 141 (1984), 1356-1364.
28. B. Seltzer, P. Zolnouni, M. Nunez, R. Goldman, D. Kumar, J. Ieni and S. Richardson, Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial, Arch Neurol 61 (2004), 1852-1856.
29. R. Spiegel, C. Brunner, D. Ermini-Funfschilling, A. Monsch, M. Notter, J. Puxty and L. Tremmel, A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients), J Am Geriatr Soc 39 (1991), 339-347.
30. R.G. Stern, R.C. Mohs, M. Davidson, J. Schmeidler, J. Silverman, E. Kramer-Ginsberg, T. Searcey, L. Bierer and K.L. Davis, A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration, Am J Psychiatry 151 (1994), 390-396.
31. L.J. Thal, M. Grundman, J. Berg, K. Ernstrom, R. Margolin, E. Pfeiffer, M.F. Weiner, E. Zamrini and R.G. Thomas, Idebenone treatment fails to slow cognitive decline in Alzheimer's disease, Neurology 61 (2003), 1498-1502.
32. B. Vellas, S. Andrieu, C. Sampaio and G. Wilcock, Disease-modifying trials in Alzheimer's disease: a European task force consensus, Lancet Neurol 6 (2007), 56-62.
33. G. Weyer, H. Erzigkeit, S. Kanowski, R. Ihl and D. Hadler, Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial, Int Psychogeriatr 9 (1997), 123-138.
34. R.F. Zec, E.S. Landreth, S.K. Vicari, E. Feldman, J. Belman, A. Andrise, R. Robbs, V. Kumar and R. Becker, Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type, Alzheimer Dis Assoc Disord 6 (1992), 89-102.